Today it was reported that the CLO of Bluebird Bio (NASDAQ: BLUE), Jason Cole, exercised options to buy 4,438 BLUE shares at $22.53 a share, for a total transaction value of $99.99K.
Following this transaction Jason Cole’s holding in the company was increased by 25.84% to a total of $3.39 million.
See today’s analyst top recommended stocks >>
Currently, Bluebird Bio has an average volume of 368K.
25 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 15 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $219.89, reflecting a -28.7% downside.
The insider sentiment on Bluebird Bio has been negative according to 82 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Jason Cole’s trades have generated a 27.2% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy.
